{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:55:32Z","timestamp":1787169332165,"version":"build-2736575974"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Pathol Microbiol"],"published-print":{"date-parts":[[2023]]},"DOI":"10.4103\/ijpm.ijpm_462_21","type":"journal-article","created":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T03:49:01Z","timestamp":1690948141000},"page":"560","source":"Crossref","is-referenced-by-count":2,"title":["Pediatric and adolescent chronic myeloid leukemia: A follow-up study in Western India"],"prefix":"10.4103","volume":"66","author":[{"given":"Dhaval","family":"Jetly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SangitaA","family":"Vanik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biren","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik","family":"Dhandapani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rukmini","family":"Bezbaruah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0377-4929.346851-1","unstructured":"Ries LA, Smith MA, Gurney JG, Linet M, Tamra T, Young JL, et al. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995. NIH Pub. No. 99-4649. Bethesda, MD: National Cancer Institute, SEER Program; 1999."},{"key":"key-10.4103\/0377-4929.346851-2","doi-asserted-by":"crossref","unstructured":"Cortes J, Deininger. BCR-ABL as a molecular target. In: Deininger M, editor. Chronic Myeloid Leukemia. 1st ed. New York: Informa Healthcare; 2006. p. 27-45.","DOI":"10.3109\/9780849379567-1"},{"key":"key-10.4103\/0377-4929.346851-3","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","author":"Sawyers","year":"1999","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0377-4929.346851-4","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1182\/blood.2018882233","article-title":"How I treat chronic myeloid leukemia in children and adolescents","author":"Hijiya","year":"2019","journal-title":"Blood"},{"key":"key-10.4103\/0377-4929.346851-5","first-page":"282","article-title":"Effectiveness of three prognostic scoring systems in predicting the response and outcome in pediatric chronic myeloid leukemia CP on frontline imatinib","author":"Ganta","year":"2017","journal-title":"Indian J Med Paediatr Oncol","ISSN":"https:\/\/id.crossref.org\/issn\/0971-5851","issn-type":"print"},{"key":"key-10.4103\/0377-4929.346851-6","unstructured":"Swerdlow SH. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017."},{"key":"key-10.4103\/0377-4929.346851-7","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"key-10.4103\/0377-4929.346851-8","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood-2007-04-038943","article-title":"How I treat chronic myeloid leukemia in the imatinib era","author":"Goldman","year":"2007","journal-title":"Blood"},{"key":"key-10.4103\/0377-4929.346851-9","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia","author":"Sokal","year":"1984","journal-title":"Blood"},{"key":"key-10.4103\/0377-4929.346851-10","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","article-title":"Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score","author":"Hasford","year":"2011","journal-title":"Blood"},{"key":"key-10.4103\/0377-4929.346851-11","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1542\/peds.2004-2473","article-title":"Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia","author":"Millot","year":"2005","journal-title":"Pediatrics"},{"key":"key-10.4103\/0377-4929.346851-12","first-page":"142","article-title":"The biology of chronic myelogenous leukemia in childhood and young adolescents: An Indian perspective","author":"Chandra","year":"2018","journal-title":"Indian J Med Paediatr Oncol","ISSN":"https:\/\/id.crossref.org\/issn\/0971-5851","issn-type":"print"},{"key":"key-10.4103\/0377-4929.346851-13","first-page":"260","article-title":"Chronic myeloid leukemia in children and adolescents: A single center experience from Eastern India","author":"Raut","year":"2013","journal-title":"South Asian J Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/2278-330X","issn-type":"print"},{"key":"key-10.4103\/0377-4929.346851-14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/ijh.ijh_28_17","article-title":"Evaluation of chronic myeloid leukemia patients and their molecular responses to tyrosine kinase inhibitors in Erbil city, Iraq","author":"Hasan","year":"2018","journal-title":"Iraqi J Hematol","ISSN":"https:\/\/id.crossref.org\/issn\/2072-8069","issn-type":"print"},{"key":"key-10.4103\/0377-4929.346851-15","first-page":"1051","article-title":", Nagai A, Tang L, Tokuda M.Investigation on hyperuricemia in children with obesity or various pediatric disorders, \u201cnucleosides, nucleotides and nucleic acid","author":"Kubota","year":"2011","journal-title":""},{"key":"key-10.4103\/0377-4929.346851-16","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s00277-015-2367-2","article-title":"Can prognostic scoring systems for chronic myeloid leukemia as established in adults be applied to pediatric patients?","author":"Salas","year":"2015","journal-title":"Ann Hematol"},{"key":"key-10.4103\/0377-4929.346851-17","doi-asserted-by":"crossref","first-page":"74","DOI":"10.4103\/1110-1067.216112","article-title":"Cytogenetic and molecular response of EUTOS risk groups in children with chronic myeloid leukemia chronic phase on imatinib treatment","author":"Ganta","year":"2017","journal-title":"Egypt J Hematol"},{"key":"key-10.4103\/0377-4929.346851-18","doi-asserted-by":"crossref","unstructured":"Suttorp M, Thiede C, Tauer JT, Roettgers S, Sedlacek P, Harbott J, et al. Chronic myeloid leukemia in pediatrics \u2013 first results from study CML-PAED II. 2009. Blood. 2009;114:342.","DOI":"10.1182\/blood.V114.22.342.342"},{"key":"key-10.4103\/0377-4929.346851-19","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1200\/JCO.2010.32.7114","article-title":"Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: Results of the French national phase IV trial","author":"Millot","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["Indian Journal of Pathology and Microbiology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:50:53Z","timestamp":1787165453000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijpm.ijpm_462_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"alternative-id":["346851"],"URL":"https:\/\/doi.org\/10.4103\/ijpm.ijpm_462_21","relation":{},"ISSN":["0377-4929"],"issn-type":[{"value":"0377-4929","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]}}}